Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374907
Status:
COMPLETED
Last Update Posted:
2015-05-07
First Post:
2006-09-07
Brief Title:
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Mechanism of Action and Efficacy of Saxagliptin BMS-477118 in the Treatment of Type 2 Diabetic Patients
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research study is to learn whether Saxagliptin can improve the bodys ability to make its own insulin and lower blood sugar in people with type 2 diabetes
Detailed Description:
All subjects will participate in a lead-in period and qualifying subjects will continue into a short-term randomized treatment period Subjects who complete the short-term period will be eligible to enter the long term extension period Also subjects who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to receive open-label metformin added onto their blinded study medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None